Venezuela Device Regulation: Statute, Decree and Circular Layers

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

The operating characteristic of Venezuelan medical device regulation is that statutory law supplies the basis of authority while internal circulars supply the executing rules. In the relationship between the two, the circular ranks ahead of the statute in terms of operability, because statutory texts are principled and old, whereas circulars are specific and immediate.

All three key changes of 2024 to 2026 took effect through a circular or a decree (Decreto N° 4.944, Circular N° DGSACS/0002/2025 and Circular N° DGSACS-008/2026), and none came from an amendment to a law. That fact is itself a confirmation of the judgment above, and it is the empirical basis on which a monitoring system for this market should be designed.

The consequence is a design requirement rather than a preference. A compliance system built on the assumption that obligations change when statutes change will hold an accurate picture of 1998 and 2000 and an inaccurate picture of the present. A system built on the assumption that obligations change when a circular is signed will hold the opposite balance, which is the one that matters commercially.

The hierarchy is not a criticism of the system; it is a description of how the system produces rules at a pace that matches administrative reality. A statute takes years to amend and must therefore stay general. A circular can be signed in a week and can therefore be specific. The asymmetry is functional, and the only thing it demands of a foreign manufacturer is that the monitoring routine be built for the layer where change actually occurs.

That demand has a corollary for documentation. If the operative rule is a one-page circular, then the one-page circular is the document that must be retrievable, in its original form, at the moment a shipment is questioned. A file that contains a summary of the circular but not the circular itself is incomplete in exactly the situation where completeness is tested.

A workable monitoring routine therefore has three elements: a defined watch list limited to the bodies that issue documents affecting the product, a fixed interval short enough that no shipment can move between two checks of a changed rule, and a person named as responsible for reading each new document rather than merely receiving it. The third element is the one most often missing, and its absence is why monitoring systems frequently exist on paper while failing in practice.

2. Legal basis

InstrumentReference numberPublication dateArticle / key point
Ley Orgánica de Salud (Organic Health Law)Gaceta Oficial N° 36.579November 11, 1998Statutory layer (1998)
Ley de Medicamentos (Medicines Law)Gaceta Oficial N° 37.006August 3, 2000Statutory layer (2000)
Decreto N° 4.944 (customs tariff)G.O. N° 6.804 ExtraordinarioApril 25, 2024Decree layer, effective May 25, 2024
Circular N° DGSACS/0002/2025DGSACS/0002/2025October 28, 2025Circular layer, effective the same day
Circular N° DGSACS-008/2026DGSACS-008/2026July 9, 2026Circular layer

3. Expert insights

Insight 1: circulars take effect immediately. Circular N° DGSACS/0002/2025 was issued on October 28, 2025 and entered into force on the same day, leaving no transition period. By contrast, Decreto N° 4.944 allowed a vacatio legis of 30 days from publication. The different rhythm of the two instrument types means that a company cannot adapt to a circular-driven change by waiting for a transition period, because none is granted.

Insight 2: circulars have no stable advance notice mechanism, so monitoring must be continuous. Circulars are signed by the director general of SACS, as with Circular N° DGSACS-008/2026, signed by Dra. Esperanza Briceño Godoy, and their issuance follows no regular cadence. What a company needs is continuous monitoring, not periodic searching, because a periodic search that happens to fall on the wrong side of a publication date produces a compliance gap that lasts until the next search.

Insight 3: this characteristic imposes a requirement on compliance methodology. In markets dominated by statute, compliance can be organized around the legal text plus an update cycle, with an annual review as the backbone. In Venezuela that model fails, and it must be replaced by event-driven continuous monitoring, in which the trigger is the publication of a document rather than the passage of a year.

The methodological point is worth stating separately, because it is the one most often lost in practice. An annual review is not simply too slow in Venezuela; it is structurally unable to detect the events that matter, since the events leave no trace in the statute and may not be indexed anywhere that a periodic search would look. The monitoring design has to follow the document type, not the calendar.

4. Practical recommendations

  1. Maintain a dedicated monitoring list for SACS circulars, with a monitoring frequency of no less than once a week, and re-check it before every shipment.
  2. Retain the original text of each circular in preference to secondary commentary. Secondary commentary often circulates faster than it is accurate and does not carry a mark when it becomes obsolete.
  3. Within the internal compliance system, establish the circular layer as a separate document level, managed alongside law, regulation and resolution rather than folded into any of them.
  4. In the cooperation agreement with the authorized representative, state that the representative has a duty to notify changes in circulars proactively, and agree a notification deadline.

5. Verification checklist

  • □ Established a dedicated monitoring list for SACS circulars with a defined frequency
  • □ Obtained and archived the original texts of Circular N° DGSACS/0002/2025 and DGSACS-008/2026
  • □ Created a separate circular layer in the internal document ledger
  • □ Agreed the duty to notify circular changes, and the deadline for notification, in the agreement with the authorized representative
  • □ Recorded the date of this verification, October 29, 2026

Regulatory information verified as of October 29, 2026.

For a Venezuela market-entry feasibility assessment covering your specific product, contact the GRZAN regulatory team. GRZAN supports manufacturers, importers and authorized representatives with device registration in Venezuela: weekly circular monitoring, maintenance of the circular layer in the compliance file, and notification arrangements written into representative agreements. Reach us at info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail